Greg Bonfiglio of Proteus Ventures to Speak at Stem Cell Summit (Apr 2013 Boston)

Monrovia, CA, April 11, 2013 --(PR.com)-- Gregory Bonfiglio from Proteus Venture Partners, will give a presentation on “Funding for Regenerative Medicine Technologies: Opportunities And Challenges” at the Stem Cell Summit 2013 (Apr 29-30, 2013 in Boston, MA).

Greg Bonfiglio is a Managing Partner of Proteus Ventures and Chair of the Centre for Commercialization of Regenerative Medicine (CCRM). He will explore the significant opportunities and challenges in commercializing stem cell research and its applications to treat disease from a technical, financial, intellectual property and reimbursement perspective – keeping stem cell technology and therapeutics in context relative to other technology sectors.

Mr. Bonfiglio is the Founder & Managing Partner of Proteus, LLC – an investment and advisory firm focused solely on Regenerative Medicine. Mr. Bonfiglio was an early investor in the field of regenerative medicine. He is on the Boards of California Stem Cell (a company specializing in hESC tools and therapeutics), and StemCyte, Inc. (a company specializing in cord blood storage and therapeutics). He also is the Chairman of the Board of the Centre for Commercialization of Regenerative Medicine (a Regeneratice Medicine Translation Center in Toronto, Canada), and is Chairman of the Advisory Board for the Regenerative Medicine Coalition.

The 2013 Stem Cell Summit includes two parallel tracks including joint sessions. This summit provides cutting-edge information on developments in all areas of stem cell research including the biology, medicine, applications, regulations, and commercialization of stem cells.

Track A: Stem Cell Research & Regenerative Medicine:
Joint Session: Funding Opportunities
Joint Session: Regulatory Guidance & Updates
Session: Advances in iPS & ES Cells
Session: Advances in Adult Stem Cells
Session: New Paradigms for Cell Therapy

Track B: Stem Cell Commercialization & Partnering:
Joint Session: Funding Opportunities
Joint Session: Regulatory Guidance & Update
Session: Novel Technologies in Stem Cell Research
Session: Overcoming Challenges in Clinical Development
Session: Commercialization: Bringing Therapeutics to Market
Session: Partnerships & Acquisitions